drugset / Trial / NCT01039701

4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease

NCT01039701

Phase 2 Completed 99 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary purpose of the study is to determine the safety and tolerability of AZD1446 vs Placebo given as an add-on treatment to Donepezil for 4 weeks in patients with mild to moderate Alzheimer's disease.

Timeline

Start
2009-12
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1446 Small molecule 30 mg Oral
Subject AZD1446 Small molecule 60 mg Oral

Indications

No indication recorded.